This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. Hedley Rees has written a book on pharma supply chains that is eye-opening and downright scary. Can patients really be confident in pharma supply chains? Why would a pharma company take risks like these? Patients should be scared.
This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory changes, and evolving market dynamics, requiring industry leaders to adopt innovative strategies in order to remain competitive.
M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma industry.
Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. Supply Chain Management Due to geopolitical and climate-related challenges , Pharma supply chain disruptions are becoming increasingly common and complex.
Challenges in Implementing AI So, does AI mark the end of laborious processes in pharma marketing? Pharma marketers rely on information technology (IT) expertiseeither internal or outsourcedto evolve back-end technology in lockstep with industry trends. The answer is yes and no.
A major new £400 million public-private collaboration has launched in the UK, aimed at enhancing the life sciences sector’s economic growth and the competitiveness over the next five years. The post Innovative pharma-government partnership to enhance UK clinical trials appeared first on European Pharmaceutical Review.
UKRI highlighted that overall, these investments will “enhance the UK’s global competitiveness by supporting research and innovation that leads to new and disruptive biomanufacturing processes across the UK.” Curious about sustainability in pharmaceuticalmanufacturing and the supply chain?
In pursuit of increased competitiveness and bottom-line impact, pharmaceuticalmanufacturers face increasing pressure to fast-track technological innovation while maintaining regulatory compliance. technology initiatives.
Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. 1 Every major pharmaceuticalmanufacturer in the UK and Ireland is investing in making their operations and supply chains more environmentally friendly.
Pharmaceuticalmanufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions.
The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. The global pharmaceuticalmanufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. Let’s find out!
This article outlines how developers can utilize sustainability initiatives to boost revenue, reduce costs, and advance innovation, ensuring a strategic, long-term, and more sustainable position in today’s competitive landscape. Continued innovation is crucial in enhancing sustainability within pharma and the broader biotech industry.
What trends are you seeing in the pharma space? Packaging solutions for track and trace are becoming increasingly important and can be considered emerging trends” Next is ensuring end-to-end connectivity of information from the point of manufacture to when it reaches the customer. These are key areas that are always on trend.
Having a healthy and sustainable pharmaceutical sector is both a necessary requirement and a good one for society. Talking about the integrated supply chain that is always in play with France and Germany, he warned of continuous competition that could pose a gradual risk to Italy’s research basis in development research.
This is borne out of the fact that while nearly three-quarters are confident in the education and training for those in the pharma sector, just 64% are confident with the industry’s ability to source engineers against competition from other sectors. Manufacturing agility: Index score 6.5/10.
It is noteworthy that Malaysia has a pharmaceuticalmanufacturing sector that almost exclusively produces generic drugs, with sales revenues amounting to only 1.5% However, they face increasing competition from foreign generic drug suppliers, which have established themselves in the market for public tenders.
In light of the Covid-19 pandemic, the war in Ukraine, and the Russian gas supply issue, several countries have called for onshoring, also referred to as reshoring; the bringing back of pharma production to locations within national borders to mitigate costs, supply issues, and concerns regarding bilateral relations.
In an age of disruption, technology is key to enabling pharmaceuticalmanufacturers monitor, track and control shipments and their processes. Pharmaceutical firms are changing the way they do business; the future winners will be highly automated and digitalised.
Pierre Socha, partner at Amadeus Capital Partners, London, UK, predicts that larger pharmaceutical companies may have similar interests. Most pharmas will buy biotech companies or smaller pharma groups for the quality of their clinical assets and the drugs on their developments,” he says.
Impact on drug pricing and affordability Increased API costs may force some manufacturers to reduce output or exit the market entirely, reducing competition and potentially driving price inflation” Rising production costs due to tariffs could lead to higher drug prices, particularly in markets where pricing pressures are already a concern.
Top-line differences between list price and MFP obscure the impact of discounts and rebates that PBMs and MCOs can secure from manufacturers in exchange for coverage or preferred access. In highly competitive categories like diabetes, net price could be half of the list price.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content